Hi,
http://www.technologytransfertactics.com/content/ipra/pharma/
Link above will give you a taste of what royalties are like.
Vast majority of pharma royalty rates are less than 10%.
Lani is unlikely to grab a figure as high as relenza imo.
It faces severe competition from off patent relenza,as will relenza, initially thru the TRIP provisions of GATT[ala recent India/Mexico deal], and post 2013 when patent expiry for relenza commences.
Development of a universal flu vax , also a danger, but probably not in the next decade.
Other drugs in BTA's pipeline may or may not come to fruition, and even if they do, not necessarily that profitable[remember common cold drug very unlikely to attract anything but very restricted subsidy from governments].
Maybe management also believes in these difficulties, and with their stated aim of trying to build a big research company, they will be reluctant to spit out cash from short term windfalls?
Question is, will I still be alive when, or if, this company finally pays out?
Was looking to buy in, but the more I looked at this company, at the royalty rates,patent expiry and the virology of swine flu, put money in other things.
Proved to be a lucky or wise decision so far.
Hey, but I thought that BHP was overpriced at 16 bucks a few years ago, and sold.
Wise not to take anything I say too seriously.
- Forums
- ASX - By Stock
- BTA
- i have no knowledge
i have no knowledge, page-10
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online